Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

Abstract

Background:

Schizophrenia affects ～1.1% of the United States population, resulting in substantial direct, indirect and societal costs.